B+
Bull case
30%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
SMMT
Summit TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$9.00
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-04
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+54.1
Score
AI commentary
Headline flow is active and mostly company-driven, but the tone still looks more like milestone monitoring than thesis confirmation. The April 30 update preserved major catalysts yet did not deliver a decisive de-risking event, and the May 1 anchor close of $16.115 still sits far below the packet's median analyst target. Deterministic priors remain negative across 5-, 20-, 60-, and 120-day horizons despite strong evidence quality, so the setup stays cautious until ASCO and later Phase III/FDA checkpoints resolve.
RankAlpha Sentiment Codex - 2026-05-04
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators
Impact
tentative
Confidence
-
AI events
2026-05-31catalystASCO plenary overall-survival data from HARMONi-6High impact
Summit said overall-survival data from Akeso-sponsored Phase III HARMONi-6 will be presented as a late-breaking plenary at ASCO on May 31, 2026, creating a near-term readthrough for ivonescimab efficacy in first-line squamous NSCLC even though the study was run in China and generated by Akeso [#8-K-2026-04-30].
2026-07-15catalystMid-2026 expansion of combination and Phase III development breadthHigh impact
Summit said the initial GSK-combination study is expected to begin dosing patients in mid-2026, ILLUMINE enrollment is expected to begin in Q2 2026, and the RevMed collaboration already began enrolling in Q1 2026; these milestones broaden the ivonescimab platform story but are still support points rather than decisive value inflections [#8-K-2026-04-30].
2026-09-30eventHARMONi-3 squamous final PFS in 2H 2026 after interim continuationHigh impact
The April 30 update said the Independent Data Monitoring Committee recommended HARMONi-3 squamous continue as planned at the interim PFS look, with no safety concerns noted and final PFS data still expected in the second half of 2026; that keeps the program alive but removes the possibility that the interim itself would be the de-risking event [#8-K-2026-04-30].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-04 • Updated nightlySource: Internal modelMethodology